Phase 3 Readout~month

Phase 3 Topline: A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia

Drug
lb-102
Indication
Schizophrenia

Other upcoming events for LBRX

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Ef
Phase 2 ReadoutPhase 2 Readout: lb-102
Phase 2 ReadoutPhase 2 Readout: lb-102
Phase 2 ReadoutPhase 2 Readout: lb-102

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia — LBRX Phase 3 Readout | BioSniper